Aripiprazole lauroxil (Aristada) vs Brexpiprazole (Rexulti)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2/D3 and serotonin 5-HT1A receptor · full Schizophrenia pipeline
Aripiprazole lauroxil (Aristada)
Marketed by Alkermes plc
NCT01469039 · Phase 3 · completed
The trial was randomized, quadruple-blinded, and placebo-controlled, with 623 participants assigned to aripiprazole lauroxil 441 mg, 882 mg, or placebo. Its primary clinical symptom endpoint, change in PANSS total score at day 85, was significantly better with both active doses than with placebo (p<0.001 for each comparison).
Reported efficacy
The Change From Baseline at Day 85 in Positive and Negative Syndrome Scale (PANSS) Total Score (Data collected from baseline to day 85): The Change From Baseline at Day 85 in Positive and Negative Syndrome Scale (PANSS) Total Score (Data collected from baseline to day 85): Aripiprazole Lauroxil 441 mg -20.9 units on a scale (Standard Error 1.39) | Aripiprazole Lauroxil 882 mg -21.8 units on a scale (Standard Error 1.35) vs Placebo -9.8 units on a scale (Standard Error 1.39) (met)
Result source: NCT01469039
Brexpiprazole (Rexulti)
Marketed by Otsuka Holdings and partners
NCT01393613 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial in 674 patients with acute schizophrenia, using a validated symptom-severity scale (PANSS) as the primary measure. The pooled comparison of the two higher doses against placebo reached statistical significance (p=0.0093), and the 4 mg dose was significant on its own (p=0.0022), but the 1 mg and 2 mg doses individually did not separate from placebo, so the result was only partially met.
Next expected readout: August 2027 · NCT07742280 (registry estimate)
Reported efficacy
Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score: Change from baseline to Week 6 in PANSS total score: brexpiprazole -22.8 (SE 1.5) vs placebo -17.4 (SE 1.6); least-squares mean difference -5.33, 95% CI -9.55 to -1.10, p=0.014 (met)
Result source: NCT03198078
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Aripiprazole lauroxil (Aristada) | Brexpiprazole (Rexulti) |
|---|---|---|
| PANSS total, change | -21.8 vs -9.8−12 vs placeboNCT014690391 other result
| -16.6 vs -13.5−3.1 vs placeboNCT0139361371 other results
|
| CGI-S, change | -0.5 vs -0.9+0.4 vs placeboNCT016264562 other results
| -1.0 vs -0.8−0.2 vs placeboNCT0139361371 other results
|
| PANSS response | —Not reported | 38.5% vs 31.7%+6.8 vs placeboNCT013936138 other results
|
| PSP, change | —Not reported | 10.5 vs 8.5+2 vs placeboNCT0139361317 other results
|
| Relapse (% of patients) | —Not reported | 13.5% vs 38.5%−24.9 vs placeboNCT01668797 |
PANSS total, change
- Aripiprazole lauroxil (Aristada)
- -21.8 vs -9.8−12 vs placeboNCT01469039
1 other result
- -20.9 vs -9.8 NCT01469039
- Brexpiprazole (Rexulti)
- -16.6 vs -13.5−3.1 vs placeboNCT01393613
71 other results
- -20.7 vs -12.0 NCT01396421
- -14.9 vs -7.6 NCT01451164
- -14.1 vs -11.9 NCT01393613
- -14.0 vs -6.6 NCT01451164
- -13.1 vs -11.1 NCT01393613
- -12.3 vs -5.7 NCT01451164
- -10.7 vs -8.9 NCT01393613
- -11 vs -6 NCT01451164
- -8.7 vs -6.6 NCT01393613
- -7.9 vs -4.5 NCT01451164
- -4.3 vs -3.5 NCT01393613
- -4.6 vs -3.1 NCT01451164
- -20 vs -13.5 NCT01393613
- -19.6 vs -12.0 NCT01396421
- -11.5 vs -7.6 NCT01451164
- -17.3 vs -11.9 NCT01393613
- -11.1 vs -6.6 NCT01451164
- -15.6 vs -11.1 NCT01393613
- -11.2 vs -5.7 NCT01451164
- -12.6 vs -8.9 NCT01393613
- -9.4 vs -6 NCT01451164
- -8.4 vs -6.6 NCT01393613
- -6.8 vs -4.5 NCT01451164
- -5.6 vs -3.5 NCT01393613
- -3.4 vs -3.1 NCT01451164
- -16.9 vs -13.5 NCT01393613
- -8.3 vs -7.6 NCT01451164
- -14.5 vs -11.9 NCT01393613
- -8.1 vs -6.6 NCT01451164
- -14.0 vs -11.1 NCT01393613
- -8.4 vs -5.7 NCT01451164
- -11.6 vs -8.9 NCT01393613
- -6.9 vs -6 NCT01451164
- -7.6 vs -6.6 NCT01393613
- -5.1 vs -4.5 NCT01451164
- -3.3 vs -3.5 NCT01393613
- -2.7 vs -3.1 NCT01451164
- -14.9 vs -12.0 NCT01396421
- -22.8 vs -17.4 NCT03198078
- -20 vs -15.9 NCT01810380
- -22.9 vs -19.4 NCT02054702
- -17.9 vs -10.8 NCT01396421
- -14.1 vs -8.9 NCT01396421
- -11.1 vs -7.6 NCT01396421
- -8.9 vs -5.1 NCT01396421
- -4.9 vs -2.9 NCT01396421
- -18.6 vs -10.8 NCT01396421
- -16.5 vs -8.9 NCT01396421
- -12.8 vs -7.6 NCT01396421
- -9.5 vs -5.1 NCT01396421
- -4.4 vs -2.9 NCT01396421
- -11.9 vs -10.8 NCT01396421
- -8.9 vs -8.9 NCT01396421
- -5.7 vs -7.6 NCT01396421
- -3.3 vs -5.1 NCT01396421
- -2.5 vs -2.9 NCT01396421
- 0.6 vs 6.9 NCT01668797
- 3.3 vs 11.2 NCT01668797
- -2.7 vs 3.3 NCT01668797
- 2.5 vs 10.5 NCT01668797
- -1.9 vs 2.9 NCT01668797
- 1.6 vs 9.2 NCT01668797
- 0.8 vs 6.2 NCT01668797
- 1.6 vs 6.6 NCT01668797
- 0.8 vs 4.1 NCT01668797
- 0.5 vs 3.6 NCT01668797
- -9.8 vs -14.4 NCT00905307
- -18.7 vs -14.4 NCT00905307
- -16.2 vs -14.4 NCT00905307
- -18.3 vs -14.4 NCT00905307
- -3.7 vs -0.3 NCT03526354
CGI-S, change
- Aripiprazole lauroxil (Aristada)
- -0.5 vs -0.9+0.4 vs placeboNCT01626456
2 other results
- -0.3 vs -0.9 NCT01626456
- -0.2 vs -0.9 NCT01626456
- Brexpiprazole (Rexulti)
- -1.0 vs -0.8−0.2 vs placeboNCT01393613
71 other results
- -1.1 vs -0.8 NCT01396421
- -0.8 vs -0.6 NCT01451164
- -0.8 vs -0.7 NCT01393613
- -1.0 vs -0.7 NCT01396421
- -0.8 vs -0.5 NCT01451164
- -0.7 vs -0.6 NCT01393613
- -0.7 vs -0.5 NCT01396421
- -0.6 vs -0.4 NCT01451164
- -0.6 vs -0.4 NCT01393613
- -0.6 vs -0.5 NCT01396421
- -0.5 vs -0.4 NCT01451164
- -0.4 vs -0.4 NCT01393613
- -0.4 vs -0.3 NCT01396421
- -0.4 vs -0.3 NCT01451164
- -0.2 vs -0.1 NCT01393613
- -0.2 vs -0.1 NCT01396421
- -0.2 vs -0.1 NCT01451164
- -1.2 vs -0.8 NCT01393613
- -1.2 vs -0.8 NCT01396421
- -0.6 vs -0.6 NCT01451164
- -1.0 vs -0.7 NCT01393613
- -1.1 vs -0.7 NCT01396421
- -0.6 vs -0.5 NCT01451164
- -0.8 vs -0.6 NCT01393613
- -1.0 vs -0.5 NCT01396421
- -0.5 vs -0.4 NCT01451164
- -0.7 vs -0.4 NCT01393613
- -0.7 vs -0.5 NCT01396421
- -0.5 vs -0.4 NCT01451164
- -0.4 vs -0.4 NCT01393613
- -0.5 vs -0.3 NCT01396421
- -0.3 vs -0.3 NCT01451164
- -0.2 vs -0.1 NCT01393613
- -0.2 vs -0.1 NCT01396421
- -0.1 vs -0.1 NCT01451164
- -0.9 vs -0.8 NCT01393613
- -0.5 vs -0.6 NCT01451164
- -0.8 vs -0.7 NCT01393613
- -0.5 vs -0.5 NCT01451164
- -0.7 vs -0.6 NCT01393613
- -0.5 vs -0.4 NCT01451164
- -0.6 vs -0.4 NCT01393613
- -0.4 vs -0.4 NCT01451164
- -0.3 vs -0.4 NCT01393613
- -0.3 vs -0.3 NCT01451164
- -0.1 vs -0.1 NCT01393613
- -0.1 vs -0.1 NCT01451164
- -0.8 vs -0.8 NCT01396421
- -0.7 vs -0.7 NCT01396421
- -0.6 vs -0.5 NCT01396421
- -0.3 vs -0.5 NCT01396421
- -0.2 vs -0.3 NCT01396421
- -0.1 vs -0.1 NCT01396421
- -0.2 vs 0.3 NCT01668797
- 0.0 vs 0.6 NCT01668797
- -0.3 vs 0.3 NCT01668797
- 0 vs 0.6 NCT01668797
- -0.2 vs 0.2 NCT01668797
- -0.0 vs 0.5 NCT01668797
- -0.0 vs 0.4 NCT01668797
- -0.0 vs 0.3 NCT01668797
- -0.9 vs -0.8 NCT03198078
- -0.0 vs 0.3 NCT01668797
- -0.1 vs 0.2 NCT01668797
- -1.2 vs -0.9 NCT01810380
- -1.6 vs -1.3 NCT02054702
- -0.4 vs -0.8 NCT00905307
- -1.0 vs -0.8 NCT00905307
- -0.9 vs -0.8 NCT00905307
- -1.1 vs -0.8 NCT00905307
- -0.3 vs -0.1 NCT03526354
PANSS response
- Aripiprazole lauroxil (Aristada)
- —Not reported
- Brexpiprazole (Rexulti)
- 38.5% vs 31.7%+6.8 vs placeboNCT01393613
8 other results
- 49.7% vs 31.7% NCT01393613
- 43.6% vs 31.7% NCT01393613
- 43.6% vs 28.2% NCT03198078
- 48.7% vs 32.1% NCT01810380
- 40.5% vs 49.5% NCT00905307
- 57.3% vs 49.5% NCT00905307
- 46.7% vs 49.5% NCT00905307
- 51.6% vs 49.5% NCT00905307
PSP, change
- Aripiprazole lauroxil (Aristada)
- —Not reported
- Brexpiprazole (Rexulti)
- 10.5 vs 8.5+2 vs placeboNCT01393613
17 other results
- 13.2 vs 10.3 NCT01396421
- 6.8 vs 5.8 NCT01393613
- 13.1 vs 8.5 NCT01393613
- 12.7 vs 10.3 NCT01396421
- 7.1 vs 5.8 NCT01393613
- 11.7 vs 8.5 NCT01393613
- 7.0 vs 5.8 NCT01393613
- 11.8 vs 10.3 NCT01396421
- 18.6 vs 12.6 NCT01668797
- 15.1 vs 10.3 NCT01668797
- 18.9 vs 17.8 NCT01668797
- 15.2 vs 11.4 NCT01668797
- 13 vs 9.4 NCT01810380
- 4.5 vs 7.6 NCT00905307
- 11.4 vs 7.6 NCT00905307
- 10.7 vs 7.6 NCT00905307
- 12.2 vs 7.6 NCT00905307
Relapse (% of patients)
- Aripiprazole lauroxil (Aristada)
- —Not reported
- Brexpiprazole (Rexulti)
- 13.5% vs 38.5%−24.9 vs placeboNCT01668797
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety
Coverage. Aripiprazole lauroxil (Aristada): 6 of 6 rows · Brexpiprazole (Rexulti): 6 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Aripiprazole lauroxil (Aristada) Rows use multiple source trials | Brexpiprazole (Rexulti) Rows use multiple source trials |
|---|---|---|
| CGI-S absolute change · score No placebo or comparator arm | -0.2 scorea,b,c,d NCT02634320 · Phase 4 · registry result, not featured evidence 2 other source trials-0.1 scoreHigh NCT01895452 · Phase 3 · registry result, not featured evidence -0.1 scoreLow NCT01895452 · Phase 3 · registry result, not featured evidence | -0.48 score @ 52wke,a,b,c,d NCT01397786 · Phase 3 · registry result, not featured evidence show 2 more doses-0.55 score @ 52wk NCT01397786 · Phase 3 · registry result, not featured evidence -0.97 score @ 52wk NCT01397786 · Phase 3 · registry result, not featured evidence |
| PANSS Total absolute change · score No placebo or comparator arm | -0.9 scoreHighe,b,c,d NCT01895452 · Phase 3 · registry result, not featured evidence show 1 more dose-0.7 scoreLow NCT01895452 · Phase 3 · registry result, not featured evidence | -19 scoree,b,c,d NCT03238326 · Phase 3 show 3 more doses-18.44 score NCT03238326 · Phase 3 -20.14 score NCT03238326 · Phase 3 -19.76 score NCT03238326 · Phase 3 |
| Dropout rate | 35.1%882 mgf NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3 show 6 more results37.2%441 mg NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3 31.8%ALKS 9072, High NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3 31.8%ALKS 9072, Low NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3 31.4% NCT02634320 · Phase 4 · registry result, not featured evidence 12.4%High NCT01895452 · Phase 3 · registry result, not featured evidence 6.2%Low NCT01895452 · Phase 3 · registry result, not featured evidence | 30.6%2 mgg NCT01393613 · Phase 3 show 45 more results29.3%4 mg NCT01393613 · Phase 3 32.5%1 mg NCT01393613 · Phase 3 —2 mg NCT01396421 · Phase 3 31.9%2 mg NCT01396421 · Phase 3 32.8%4 mg NCT01396421 · Phase 3 —4 mg NCT01396421 · Phase 3 —0.25 mg NCT01396421 · Phase 3 37.8%0.25 mg NCT01396421 · Phase 3 0%De Novo (Conversion Period) NCT03238326 · Phase 3 —De Novo (OLT Period) NCT03238326 · Phase 3 —Prior & Current Brexpiprazole (OLT NCT03238326 · Phase 3 —Prior Aripiprazole & Current Brexp NCT03238326 · Phase 3 —Prior Placebo & Current Brexpipraz NCT03238326 · Phase 3 —Prior and Current Brexpiprazole NCT03238326 · Phase 3 2.7% NCT03198078 · Phase 3 — NCT01668797 · Phase 3 28.6% NCT03526354 · Phase 4 · registry result, not featured evidence 15.8%2 mg NCT02194933 · Phase 3 · registry result, not featured evidence 47.4%4 mg NCT02194933 · Phase 3 · registry result, not featured evidence 12.3%De Novo NCT01397786 · Phase 3 · registry result, not featured evidence —De Novo (Phase A) NCT01397786 · Phase 3 · registry result, not featured evidence —De Novo (Phase B) NCT01397786 · Phase 3 · registry result, not featured evidence 0%Prior Brexpiprazole NCT01397786 · Phase 3 · registry result, not featured evidence —Prior Brexpiprazole (Phase B) NCT01397786 · Phase 3 · registry result, not featured evidence —Prior Placebo NCT01397786 · Phase 3 · registry result, not featured evidence —Prior Placebo (Phase B) NCT01397786 · Phase 3 · registry result, not featured evidence 51.9% NCT01810783 · Phase 3 · registry result, not featured evidence 25.2% NCT01810380 · Phase 3 · registry result, not featured evidence 49% NCT02013622 · Phase 3 · registry result, not featured evidence 37.5% NCT02054702 · Phase 3 · registry result, not featured evidence 29.6%2 mg NCT01451164 · Phase 2/3 · registry result, not featured evidence 39.8%4 mg NCT01451164 · Phase 2/3 · registry result, not featured evidence 37.4%1 mg NCT01451164 · Phase 2/3 · registry result, not featured evidence 52.4%0.25 mg NCT00905307 · Phase 2 · registry result, not featured evidence —High-dose NCT00905307 · Phase 2 · registry result, not featured evidence 41.6%Low-dose NCT00905307 · Phase 2 · registry result, not featured evidence 41.1%Mid-dose NCT00905307 · Phase 2 · registry result, not featured evidence —Fasted Stated NCT06036108 · Phase 1 · registry result, not featured evidence —Fed Stated NCT06036108 · Phase 1 · registry result, not featured evidence 0%4 mg NCT01854944 · Phase 1 · registry result, not featured evidence 25%4 mg NCT01854944 · Phase 1 · registry result, not featured evidence 0%1 mg NCT01854944 · Phase 1 · registry result, not featured evidence 14.9%4 mg NCT01423916 · Phase 1 · registry result, not featured evidence 27.4%12 mg NCT01423916 · Phase 1 · registry result, not featured evidence —3mg NCT01289080 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | —882 mgf NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3 show 6 more results—441 mg NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3 7.3%ALKS 9072, High NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3 1.8%ALKS 9072, Low NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3 3.9% NCT02634320 · Phase 4 · registry result, not featured evidence 1.8%High NCT01895452 · Phase 3 · registry result, not featured evidence 1.5%Low NCT01895452 · Phase 3 · registry result, not featured evidence | 5.9%2 mgg NCT01393613 · Phase 3 show 45 more results7.1%4 mg NCT01393613 · Phase 3 9.2%1 mg NCT01393613 · Phase 3 —2 mg NCT01396421 · Phase 3 8.2%2 mg NCT01396421 · Phase 3 9.4%4 mg NCT01396421 · Phase 3 —4 mg NCT01396421 · Phase 3 —0.25 mg NCT01396421 · Phase 3 13.3%0.25 mg NCT01396421 · Phase 3 —De Novo (Conversion Period) NCT03238326 · Phase 3 —De Novo (OLT Period) NCT03238326 · Phase 3 —Prior & Current Brexpiprazole (OLT NCT03238326 · Phase 3 —Prior Aripiprazole & Current Brexp NCT03238326 · Phase 3 —Prior Placebo & Current Brexpipraz NCT03238326 · Phase 3 —Prior and Current Brexpiprazole NCT03238326 · Phase 3 0% NCT03198078 · Phase 3 — NCT01668797 · Phase 3 — NCT03526354 · Phase 4 · registry result, not featured evidence —2 mg NCT02194933 · Phase 3 · registry result, not featured evidence —4 mg NCT02194933 · Phase 3 · registry result, not featured evidence 3.5%De Novo NCT01397786 · Phase 3 · registry result, not featured evidence —De Novo (Phase A) NCT01397786 · Phase 3 · registry result, not featured evidence —De Novo (Phase B) NCT01397786 · Phase 3 · registry result, not featured evidence 0%Prior Brexpiprazole NCT01397786 · Phase 3 · registry result, not featured evidence —Prior Brexpiprazole (Phase B) NCT01397786 · Phase 3 · registry result, not featured evidence —Prior Placebo NCT01397786 · Phase 3 · registry result, not featured evidence —Prior Placebo (Phase B) NCT01397786 · Phase 3 · registry result, not featured evidence 15.2% NCT01810783 · Phase 3 · registry result, not featured evidence 9.3% NCT01810380 · Phase 3 · registry result, not featured evidence 6.1% NCT02013622 · Phase 3 · registry result, not featured evidence 4.7% NCT02054702 · Phase 3 · registry result, not featured evidence 10.4%2 mg NCT01451164 · Phase 2/3 · registry result, not featured evidence 15.9%4 mg NCT01451164 · Phase 2/3 · registry result, not featured evidence 16.5%1 mg NCT01451164 · Phase 2/3 · registry result, not featured evidence 7.1%0.25 mg NCT00905307 · Phase 2 · registry result, not featured evidence —High-dose NCT00905307 · Phase 2 · registry result, not featured evidence 4.5%Low-dose NCT00905307 · Phase 2 · registry result, not featured evidence 5.6%Mid-dose NCT00905307 · Phase 2 · registry result, not featured evidence —Fasted Stated NCT06036108 · Phase 1 · registry result, not featured evidence —Fed Stated NCT06036108 · Phase 1 · registry result, not featured evidence —4 mg NCT01854944 · Phase 1 · registry result, not featured evidence —4 mg NCT01854944 · Phase 1 · registry result, not featured evidence —1 mg NCT01854944 · Phase 1 · registry result, not featured evidence 6.8%4 mg NCT01423916 · Phase 1 · registry result, not featured evidence 12.3%12 mg NCT01423916 · Phase 1 · registry result, not featured evidence —3mg NCT01289080 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 1.9%882 mgf NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3 show 6 more results1.4%441 mg NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3 4.1%ALKS 9072, High NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3 0%ALKS 9072, Low NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3 9.8% NCT02634320 · Phase 4 · registry result, not featured evidence 1.8%High NCT01895452 · Phase 3 · registry result, not featured evidence 0%Low NCT01895452 · Phase 3 · registry result, not featured evidence | 2.2%2 mgg NCT01393613 · Phase 3 show 45 more results2.2%4 mg NCT01393613 · Phase 3 2.5%1 mg NCT01393613 · Phase 3 2.2%2 mg NCT01396421 · Phase 3 —2 mg NCT01396421 · Phase 3 —4 mg NCT01396421 · Phase 3 1.1%4 mg NCT01396421 · Phase 3 4.4%0.25 mg NCT01396421 · Phase 3 —0.25 mg NCT01396421 · Phase 3 0%De Novo (Conversion Period) NCT03238326 · Phase 3 5%De Novo (OLT Period) NCT03238326 · Phase 3 —Prior & Current Brexpiprazole (OLT NCT03238326 · Phase 3 1.1%Prior Aripiprazole & Current Brexp NCT03238326 · Phase 3 3.4%Prior Placebo & Current Brexpipraz NCT03238326 · Phase 3 4.1%Prior and Current Brexpiprazole NCT03238326 · Phase 3 0.9% NCT03198078 · Phase 3 3.1% NCT01668797 · Phase 3 0% NCT03526354 · Phase 4 · registry result, not featured evidence 0%2 mg NCT02194933 · Phase 3 · registry result, not featured evidence 0%4 mg NCT02194933 · Phase 3 · registry result, not featured evidence —De Novo NCT01397786 · Phase 3 · registry result, not featured evidence 1.8%De Novo (Phase A) NCT01397786 · Phase 3 · registry result, not featured evidence 11.2%De Novo (Phase B) NCT01397786 · Phase 3 · registry result, not featured evidence —Prior Brexpiprazole NCT01397786 · Phase 3 · registry result, not featured evidence 14.9%Prior Brexpiprazole (Phase B) NCT01397786 · Phase 3 · registry result, not featured evidence —Prior Placebo NCT01397786 · Phase 3 · registry result, not featured evidence 8.9%Prior Placebo (Phase B) NCT01397786 · Phase 3 · registry result, not featured evidence 14.8% NCT01810783 · Phase 3 · registry result, not featured evidence 4.7% NCT01810380 · Phase 3 · registry result, not featured evidence 0% NCT02013622 · Phase 3 · registry result, not featured evidence 4.7% NCT02054702 · Phase 3 · registry result, not featured evidence 4.4%2 mg NCT01451164 · Phase 2/3 · registry result, not featured evidence 4.4%4 mg NCT01451164 · Phase 2/3 · registry result, not featured evidence 7%1 mg NCT01451164 · Phase 2/3 · registry result, not featured evidence 0%0.25 mg NCT00905307 · Phase 2 · registry result, not featured evidence 4.3%High-dose NCT00905307 · Phase 2 · registry result, not featured evidence 3.4%Low-dose NCT00905307 · Phase 2 · registry result, not featured evidence 5.6%Mid-dose NCT00905307 · Phase 2 · registry result, not featured evidence 0%Fasted Stated NCT06036108 · Phase 1 · registry result, not featured evidence 1.8%Fed Stated NCT06036108 · Phase 1 · registry result, not featured evidence 0%4 mg NCT01854944 · Phase 1 · registry result, not featured evidence 0%4 mg NCT01854944 · Phase 1 · registry result, not featured evidence 0%1 mg NCT01854944 · Phase 1 · registry result, not featured evidence 1.4%4 mg NCT01423916 · Phase 1 · registry result, not featured evidence 0%12 mg NCT01423916 · Phase 1 · registry result, not featured evidence 0%3mg NCT01289080 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | 882 mgf insomnia 12% (placebo 11.6%) akathisia 11.1% (placebo 4.3%) headache 8.7% (placebo 8.2%) NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3 show 6 more results441 mg akathisia 11.6% (placebo 4.3%) insomnia 9.7% (placebo 11.6%) headache 8.2% (placebo 8.2%) NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3 insomnia 10.1% weight increased 4.6% headache 3% NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3 headache 6.4% weight increased 6.4% insomnia 2.7% NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3 anxiety 5.9% NCT02634320 · Phase 4 · registry result, not featured evidence High insomnia 7.1% nasopharyngitis 4% diarrhoea 3.1% NCT01895452 · Phase 3 · registry result, not featured evidence Low diarrhoea 6.2% nasopharyngitis 6.2% toothache 6.2% NCT01895452 · Phase 3 · registry result, not featured evidence | 2 mgg insomnia 13.4% (placebo 14.7%) headache 10.8% (placebo 14.7%) agitation 8.6% (placebo 7.1%) NCT01393613 · Phase 3 show 38 more results4 mg insomnia 15.2% (placebo 14.7%) headache 10.3% (placebo 14.7%) agitation 7.1% (placebo 7.1%) NCT01393613 · Phase 3 1 mg insomnia 12.5% (placebo 14.7%) agitation 8.3% (placebo 7.1%) headache 7.5% (placebo 14.7%) NCT01393613 · Phase 3 2 mg headache 9.3% (placebo 8.2%) insomnia 8.8% (placebo 9.8%) agitation 6% (placebo 10.3%) NCT01396421 · Phase 3 4 mg headache 12.2% (placebo 8.2%) insomnia 8.3% (placebo 9.8%) agitation 7.2% (placebo 10.3%) NCT01396421 · Phase 3 0.25 mg headache 10% (placebo 8.2%) insomnia 8.9% (placebo 9.8%) schizophrenia 6.7% (placebo 9.8%) NCT01396421 · Phase 3 headache 6.4% (placebo 4.8%) nausea 6.4% (placebo 3.8%) somnolence 4.5% (placebo 4.8%) NCT03198078 · Phase 3 fatigure/tiredness 14.3% nausea 14.3% cold-like symptoms 9.5% NCT03526354 · Phase 4 · registry result, not featured evidence 2 mg headache 15.8% insomnia 10.5% irritability 10.5% NCT02194933 · Phase 3 · registry result, not featured evidence 4 mg agitation 10.5% anxiety 10.5% back pain 10.5% NCT02194933 · Phase 3 · registry result, not featured evidence insomnia 12.5% headache 9.4% agitation 9% NCT01397786 · Phase 3 · registry result, not featured evidence insomnia 8.4% weight increased 7.8% headache 6.9% NCT01397786 · Phase 3 · registry result, not featured evidence insomnia 8.4% weight increased 7.4% akathisia 6.9% NCT01397786 · Phase 3 · registry result, not featured evidence weight increased 10.5% headache 8.6% insomnia 8.1% NCT01810783 · Phase 3 · registry result, not featured evidence insomnia 8.7% (placebo 6.2%) akathisia 6% (placebo 2.5%) headache 5.3% (placebo 6.8%) NCT01810380 · Phase 3 · registry result, not featured evidence insomnia 14.3% somnolence 8.2% nausea 6.1% NCT02013622 · Phase 3 · registry result, not featured evidence akathisia 9.4% weight increased 9.4% dry mouth 7.8% NCT02054702 · Phase 3 · registry result, not featured evidence 2 mg schizophrenia 11.4% (placebo 24.1%) headache 7.9% (placebo 4.3%) constipation 7% (placebo 7.8%) NCT01451164 · Phase 2/3 · registry result, not featured evidence 4 mg schizophrenia 20.4% (placebo 24.1%) nasopharyngitis 8.8% (placebo 9.5%) vomiting 7.1% (placebo 3.4%) NCT01451164 · Phase 2/3 · registry result, not featured evidence 1 mg schizophrenia 17.4% (placebo 24.1%) nasopharyngitis 10.4% (placebo 9.5%) constipation 7% (placebo 7.8%) NCT01451164 · Phase 2/3 · registry result, not featured evidence 0.25 mg headache 14.3% (placebo 10.5%) anxiety 11.9% (placebo 10.5%) agitation 9.5% (placebo 4.2%) NCT00905307 · Phase 2 · registry result, not featured evidence High-dose akathisia 15.1% (placebo 4.2%) anxiety 10.8% (placebo 10.5%) insomnia 9.7% (placebo 16.8%) NCT00905307 · Phase 2 · registry result, not featured evidence Low-dose insomnia 13.5% (placebo 16.8%) headache 9% (placebo 10.5%) anxiety 7.9% (placebo 10.5%) NCT00905307 · Phase 2 · registry result, not featured evidence Mid-dose headache 14.4% (placebo 10.5%) insomnia 10% (placebo 16.8%) weight increased 10% (placebo 3.2%) NCT00905307 · Phase 2 · registry result, not featured evidence nausea 9.6% somnolence 9.6% diarrhoea 5.8% NCT06036108 · Phase 1 · registry result, not featured evidence vomiting 20% nausea 12.7% somnolence 12.7% NCT06036108 · Phase 1 · registry result, not featured evidence 4 mg abdominal pain 25% akathisia 25% blepharospasm 25% NCT01854944 · Phase 1 · registry result, not featured evidence 4 mg akathisia 25% dental carries 25% dyspepsia 25% NCT01854944 · Phase 1 · registry result, not featured evidence 1 mg abdominal discomfort 50% agitation 25% abdominal pain 0% NCT01854944 · Phase 1 · registry result, not featured evidence 4 mg nausea 10% (placebo 5.9%) application site dermatitis 8.6% (placebo 5.9%) dizziness 8.6% (placebo 1.5%) NCT01423916 · Phase 1 · registry result, not featured evidence 12 mg dizziness 11.9% (placebo 1.5%) akathisia 7.5% (placebo 1.5%) extrapyramidal disorder 7.5% (placebo 1.5%) NCT01423916 · Phase 1 · registry result, not featured evidence 3mg somnolence 15.8% headache 10.5% orthostatic hypotension 10.5% NCT01289080 · Phase 1 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 3 versus Phase 4.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dThe assessment timepoint is not available for both results.
- eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- fPopulation comparability has not been reviewed for 3 of these studies.
- gPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Aripiprazole lauroxil (Aristada)
show 2 more results
show 2 more results
show 2 more results
show 2 more results
Brexpiprazole (Rexulti)
show 17 more results
show 35 more results
show 35 more results
show 34 more results
show 8 more results
show 31 more results
show 31 more results
show 31 more results
show 28 more results
show 31 more results
show 31 more results
show 17 more results
+ 56 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Aripiprazole lauroxil (Aristada)'s landscape · Brexpiprazole (Rexulti)'s landscape